Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Sortiert nach
Einfacher Volltextzugriff von (fast) überall
Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...
Open Access
    Datensatz exportieren als...
  • BibTeX
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers
Clinical cancer research, 2018-05, Vol.24 (9), p.2050-2059
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
NPJ breast cancer, 2021-04, Vol.7 (1), p.44-44, Article 44
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
SAMPLING INTENSITY WITH FIXED PRECISION WHEN ESTIMATING VOLUME OF HUMAN BRAIN COMPARTMENTS
Image analysis & stereology, 2011-05, Vol.27 (3), p.143-149
2011
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)
Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-09-02-OT-09-02
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER + HER2 - Primary Breast Cancer
Clinical cancer research, 2020-08, Vol.26 (16), p.4242-4249
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3156-TPS3156
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)
Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-09-05-OT-09-05
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer
Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1024-1024
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Clinical cancer research, 2020-04, Vol.26 (15), p.3947-3957
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer
Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-04-01
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-05
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer
Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-05-PS11-05
2021
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K -Mutant, ER-Positive Metastatic Breast Cancer
Clinical cancer research, 2020-08, Vol.26 (15), p.3947-3957
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer
Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P3-P3-07-28
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P3-P3-07-13
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
PSI's Pharmaceutical Statistics Journal Club
Pharmaceutical statistics : the journal of the pharmaceutical industry, 2012-05, Vol.11 (3), p.193-193
2012
Volltextzugriff (PDF)
1 – 16 von 16
Suche als RSS-Feed
Suchergebnisse filtern
Filter anzeigen